Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive Ecosystem for early cancer detection, cancer risk prediction and autonomous AI for enhanced clinical workflows.
A Growing Ecosystem
At the core of their unified strategy is a comprehensive Ecosystem designed to support clinicians and improve patient outcomes across the entire cancer journey. The Ecosystem delivers actionable insights that enhance care quality and efficiency by integrating AI-driven technologies for lesion detection, workflow optimization and patient engagement, with decision-making insight through risk prediction and mammography quality control. Powered by AI, including physics-based algorithms and access to over 130 million images for research and development, the Ecosystem drives accurate, efficient and scalable solutions for cancer detection.
Focusing on customer obsession, the Ecosystem also provides dedicated support, professional services, and fosters an exclusive online community to ensure clinical success and operational excellence. Additionally, future multipliers like autonomous AI, intelligent report generation and image-based risk evaluation are set to redefine the standards of cancer care globally.
Transforming Risk Assessment
As part of their collaboration, Lunit and Volpara presented a combination of Lunit INSIGHT Risk and Volpara Risk Pathways, offering a comprehensive approach to breast cancer risk management.
- Lunit INSIGHT Risk uses AI-driven imaging data to predict breast cancer risk within 1-5 years, providing actionable insights based on mammography images.
- Volpara Risk Pathways incorporates clinical and lifestyle data to deliver broader, personalized risk assessments.
These solutions enable clinicians to create tailored care plans, enhance early detection strategies and ensure equitable care for diverse patient populations.
Expanding AI Innovation
At RSNA 2024, Lunit also introduced its Autonomous AI Chest X-ray Report Generation prototype. Using advanced foundation models, the system automates chest X-ray interpretations and generates structured reports. By analyzing and categorizing findings based on severity, measurement and location, the tool ensures precision and standardization in reporting.
This reduces radiologist workloads, especially in high-volume clinical environments, while improving diagnostic efficiency. By automating time-consuming processes, it enables radiologists to focus on complex and critical cases, ensuring timely and accurate patient care.
The tool also includes voice recognition capabilities, allowing radiologists to make edits and finalize reports seamlessly, further enhancing workflow flexibility and usability.
Global Market Expansion
The collaboration between Lunit and Volpara underscores their commitment to conquering cancer together and leading the global fight against cancer. Together, they aim to expand their presence in key markets by leveraging the Ecosystem, advanced AI solutions and innovative tools such as autonomous report generation.
“By integrating our complementary technologies, we are transforming the way clinicians detect cancer, predict risk, and manage workflows. This Ecosystem is more than a set of tools. It’s a global solution designed to empower healthcare providers, reduce disparities, and ultimately save more lives; the next frontier in cancer care,” said Brandon Suh, CEO of Lunit.
“Together, as part of the same family, we’re addressing some of the most pressing challenges in cancer care—from empowering clinicians with actionable insights to improving outcomes for patients around the world. We’re proud to showcase the tangible impact of this integration, which is already shaping the future of global cancer detection and care,” said Teri Thomas, CEO of Volpara Health and CBO of Lunit Cancer Screening Group.
Lunit is a provider of AI-powered solutions for cancer diagnostics and therapeutics, and Volpara Health, a Lunit company, provide mammography AI solutions for the early detection of cancer.
For more information on the companies, please visit lunit.io and www.volparahealth.com.
February 18, 2026 
